CleftGeneDB-Search

Gene: RAD51

Basic information

Tag	Content
Uniprot ID	Q06609; B0FXP0; B2R8T6; Q6FHX9; Q6ZNA8; Q9BV60;
Entrez ID	5888
Genbank protein ID	BAG36283.1; ABY59731.1; EAW92432.1; AAN87149.1; EAW92435.1; CAG38796.1; BAF84658.1; AAD49705.1; BAD18467.1; AAH01459.1; EAW92434.1; BAA02962.1; AAF69145.1; BAA03189.1;
Genbank nucleotide ID	NM_002875.4; XM_006720626.3; NM_001164270.1; XM_011521860.2; XM_011521861.2; NM_001164269.1; XM_011521858.2; XM_011521859.2; NM_133487.3; XM_011521857.2;
Ensembl protein ID	ENSP00000493712; ENSP00000267868; ENSP00000406602; ENSP00000372088; ENSP00000454176; ENSP00000433924;
Ensembl nucleotide ID	ENSG00000051180
Gene name	DNA repair protein RAD51 homolog 1
Gene symbol	RAD51
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type
Developmental stage
Data sources	Manually collected
Reference	26507587
Functional description	Plays an important role in homologous strand exchange, a key step in DNA repair through homologous recombination (HR) (PubMed:28575658). Binds to single and double-stranded DNA and exhibits DNA-dependent ATPase activity. Catalyzes the recognition of homology and strand exchange between homologous DNA partners to form a joint molecule between a processed DNA break and the repair template. Binds to single-stranded DNA in an ATP-dependent manner to form nucleoprotein filaments which are essential for the homology search and strand exchange (PubMed:26681308). Part of a PALB2-scaffolded HR complex containing BRCA2 and RAD51C and which is thought to play a role in DNA repair by HR. Plays a role in regulating mitochondrial DNA copy number under conditions of oxidative stress in the presence of RAD51C and XRCC3. Also involved in interstrand cross-link repair (PubMed:26253028).
Sequence	MAMQMQLEAN ADTSVEEESF GPQPISRLEQ CGINANDVKK LEEAGFHTVE AVAYAPKKEL 60 INIKGISEAK ADKILAEAAK LVPMGFTTAT EFHQRRSEII QITTGSKELD KLLQGGIETG 120 SITEMFGEFR TGKTQICHTL AVTCQLPIDR GGGEGKAMYI DTEGTFRPER LLAVAERYGL 180 SGSDVLDNVA YARAFNTDHQ TQLLYQASAM MVESRYALLI VDSATALYRT DYSGRGELSA 240 RQMHLARFLR MLLRLADEFG VAVVITNQVV AQVDGAAMFA ADPKKPIGGN IIAHASTTRL 300 YLRKGRGETR ICKIYDSPCL PEAEAMFAIN ADGVGDAKD 339

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

PDB ID
1B22
1N0W
5H1B
5H1C
5JZC
5NP7
5NWL
1B22

Protein disorder information

Orthologous information

Relation	Gene symbol	Entrez ID	UniProt ID	Species	Evidence	Details
1:1 ortholog	RAD51	514749	Q2KJ94	Bos taurus	Prediction	More>>
1:1 ortholog	RAD51	403568	Q8MKI8	Canis lupus familiaris	Prediction	More>>
1:1 ortholog	RAD51	102177525	A0A452G921	Capra hircus	Prediction	More>>
1:1 ortholog	RAD51	5888	Q06609	Homo sapiens	Publication	More>>
1:1 ortholog	Rad51	19361	Q08297	Mus musculus	Prediction	More>>
1:1 ortholog	RAD51	453339	A0A2I3SZ08	Pan troglodytes	Prediction	More>>
1:1 ortholog	RAD51	100141309	B0M1M6	Sus scrofa	Prediction	More>>
1:1 ortholog	RAD51	100008661	G1TCL3	Oryctolagus cuniculus	Prediction	More>>
1:1 ortholog	Rad51	499870	B5DF04	Rattus norvegicus	Prediction	More>>
1:1 ortholog	rad51	406487	Q5TYR1	Danio rerio	Prediction	More>>

Identified variants/mutations related to cleft phenotype

Gene symbol	Significant Variants/SNPS	Methods	PubMed ID
RAD51	rs1801321	Genotyping; TDT	26507587
RAD51	c.725A>G; p.Gln242Arg (heterozygous)	trio-WES and Sanger sequencing	30907510

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
rs751792276	p.Met3Val	missense variant	-	NC_000015.10:g.40698765A>G	ExAC,TOPMed
rs1335930270	p.Gln4His	missense variant	-	NC_000015.10:g.40698770G>C	gnomAD
rs944000401	p.Ala9Val	missense variant	-	NC_000015.10:g.40698784C>T	TOPMed
rs1286692919	p.Ala11Gly	missense variant	-	NC_000015.10:g.40698790C>G	gnomAD
rs1362216112	p.Asp12Asn	missense variant	-	NC_000015.10:g.40698792G>A	TOPMed
rs1246018948	p.Asp12Gly	missense variant	-	NC_000015.10:g.40698793A>G	gnomAD
NCI-TCGA novel	p.Asp12Ala	missense variant	-	NC_000015.10:g.40698793A>C	NCI-TCGA
NCI-TCGA novel	p.Asp12His	missense variant	-	NC_000015.10:g.40698792G>C	NCI-TCGA
rs1159091605	p.Val15Glu	missense variant	-	NC_000015.10:g.40698802T>A	TOPMed
rs1487695348	p.Glu18Ter	stop gained	-	NC_000015.10:g.40698810G>T	gnomAD
NCI-TCGA novel	p.Glu18Lys	missense variant	-	NC_000015.10:g.40698810G>A	NCI-TCGA
rs755132632	p.Ser19Gly	missense variant	-	NC_000015.10:g.40698813A>G	ExAC,TOPMed,gnomAD
rs781383372	p.Gln23Arg	missense variant	-	NC_000015.10:g.40698826A>G	ExAC,gnomAD
rs1200593832	p.Ile25Val	missense variant	-	NC_000015.10:g.40698831A>G	TOPMed
rs1180753546	p.Ser26Leu	missense variant	-	NC_000015.10:g.40698835C>T	gnomAD
rs778132081	p.Arg27Gln	missense variant	-	NC_000015.10:g.40698838G>A	ExAC,gnomAD
rs756713380	p.Arg27Trp	missense variant	-	NC_000015.10:g.40698837C>T	ExAC,TOPMed,gnomAD
rs1489593050	p.Glu29Gly	missense variant	-	NC_000015.10:g.40698844A>G	TOPMed
NCI-TCGA novel	p.Glu29Asp	missense variant	-	NC_000015.10:g.40698845G>T	NCI-TCGA
COSM4917851	p.Ile33Met	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000015.10:g.40701075A>G	NCI-TCGA Cosmic
rs751379027	p.Asn34Thr	missense variant	-	NC_000015.10:g.40701077A>C	ExAC,TOPMed,gnomAD
rs377571591	p.Ala35Asp	missense variant	-	NC_000015.10:g.40701080C>A	ESP,TOPMed,gnomAD
rs755292488	p.Ala35Thr	missense variant	-	NC_000015.10:g.40701079G>A	ExAC,gnomAD
rs756092232	p.Asp37Ala	missense variant	-	NC_000015.10:g.40701086A>C	ExAC,gnomAD
rs1428987216	p.Asp37Asn	missense variant	-	NC_000015.10:g.40701085G>A	gnomAD
rs756092232	p.Asp37Val	missense variant	-	NC_000015.10:g.40701086A>T	ExAC,gnomAD
rs757735432	p.Leu41Phe	missense variant	-	NC_000015.10:g.40701099G>T	ExAC,gnomAD
rs1302486714	p.Glu42Ter	stop gained	-	NC_000015.10:g.40701100G>T	gnomAD
rs779286806	p.Gly45Ala	missense variant	-	NC_000015.10:g.40701110G>C	ExAC,gnomAD
rs746224582	p.Phe46Cys	missense variant	-	NC_000015.10:g.40701113T>G	ExAC,gnomAD
rs1298742495	p.Phe46Leu	missense variant	-	NC_000015.10:g.40701114C>G	gnomAD
COSM4878945	p.His47Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000015.10:g.40701115C>A	NCI-TCGA Cosmic
RCV000192085	p.His47Arg	missense variant	Mirror movements 2 (MRMV2)	NC_000015.10:g.40701116A>G	ClinVar
rs768411477	p.His47Arg	missense variant	-	NC_000015.10:g.40701116A>G	ExAC,gnomAD
NCI-TCGA novel	p.Val49Ala	missense variant	-	NC_000015.10:g.40701122T>C	NCI-TCGA
rs999567341	p.Glu50Val	missense variant	-	NC_000015.10:g.40701125A>T	TOPMed
rs747697371	p.Val52Ile	missense variant	-	NC_000015.10:g.40701130G>A	ExAC,gnomAD
rs1313509498	p.Ala53Thr	missense variant	-	NC_000015.10:g.40701133G>A	gnomAD
rs769146109	p.Tyr54Cys	missense variant	-	NC_000015.10:g.40701137A>G	ExAC,TOPMed,gnomAD
rs145617142	p.Ala55Val	missense variant	-	NC_000015.10:g.40701140C>T	ESP,ExAC,TOPMed,gnomAD
rs45623838	p.Pro56Ser	missense variant	-	NC_000015.10:g.40701142C>T	ESP,ExAC,TOPMed,gnomAD
rs1448625265	p.Lys57Arg	missense variant	-	NC_000015.10:g.40701146A>G	gnomAD
COSM961288	p.Lys57Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000015.10:g.40701147G>T	NCI-TCGA Cosmic
rs1371546291	p.Asn62Asp	missense variant	-	NC_000015.10:g.40701160A>G	TOPMed
rs531275069	p.Ile63Thr	missense variant	-	NC_000015.10:g.40701164T>C	1000Genomes,ExAC,gnomAD
rs1427093630	p.Ile63Met	missense variant	-	NC_000015.10:g.40701165T>G	gnomAD
rs1163399253	p.Ser67Ile	missense variant	-	NC_000015.10:g.40701176G>T	NCI-TCGA Cosmic
rs1163399253	p.Ser67Asn	missense variant	-	NC_000015.10:g.40701176G>A	TOPMed
rs1163399253	p.Ser67Ile	missense variant	-	NC_000015.10:g.40701176G>T	TOPMed
rs143055953	p.Ala69Pro	missense variant	-	NC_000015.10:g.40701181G>C	ESP,TOPMed
NCI-TCGA novel	p.Ala69Ser	missense variant	-	NC_000015.10:g.40701181G>T	NCI-TCGA
rs1164062003	p.Asp72Val	missense variant	-	NC_000015.10:g.40701191A>T	TOPMed
rs1415120657	p.Lys73Arg	missense variant	-	NC_000015.10:g.40701194A>G	gnomAD
rs1218843632	p.Glu77Gly	missense variant	-	NC_000015.10:g.40706181A>G	gnomAD
rs1335853382	p.Ala78Ser	missense variant	-	NC_000015.10:g.40706183G>T	TOPMed,gnomAD
rs146489542	p.Ala79Val	missense variant	-	NC_000015.10:g.40706187C>T	1000Genomes,ExAC,gnomAD
rs1312157762	p.Lys80Glu	missense variant	-	NC_000015.10:g.40706189A>G	TOPMed
rs751930241	p.Lys80Ile	missense variant	-	NC_000015.10:g.40706190A>T	ExAC,gnomAD
rs1312603787	p.Leu81Phe	missense variant	-	NC_000015.10:g.40706194A>T	gnomAD
rs1367039588	p.Val82Ile	missense variant	-	NC_000015.10:g.40706195G>A	gnomAD
rs755778442	p.Met84Val	missense variant	-	NC_000015.10:g.40706201A>G	ExAC,gnomAD
rs777561646	p.Gly85Asp	missense variant	-	NC_000015.10:g.40706205G>A	ExAC,gnomAD
COSM1478082	p.Phe86Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000015.10:g.40706209C>A	NCI-TCGA Cosmic
rs748809229	p.His93Tyr	missense variant	-	NC_000015.10:g.40706228C>T	ExAC
rs376382204	p.Gln94Glu	missense variant	-	NC_000015.10:g.40706231C>G	ESP,TOPMed,gnomAD
rs1013168760	p.Arg96Trp	missense variant	-	NC_000015.10:g.40706237C>T	TOPMed
rs1048716857	p.Glu98Asp	missense variant	-	NC_000015.10:g.40706245G>C	TOPMed
NCI-TCGA novel	p.Glu98Asp	missense variant	-	NC_000015.10:g.40706245G>T	NCI-TCGA
rs1279669649	p.Gln101Glu	missense variant	-	NC_000015.10:g.40706252C>G	gnomAD
NCI-TCGA novel	p.Gln101His	missense variant	-	NC_000015.10:g.40706254G>C	NCI-TCGA
rs779012045	p.Ile102Val	missense variant	-	NC_000015.10:g.40706255A>G	ExAC
rs745749160	p.Ile102Met	missense variant	-	NC_000015.10:g.40706257T>G	ExAC
NCI-TCGA novel	p.Thr104Ile	missense variant	-	NC_000015.10:g.40706262C>T	NCI-TCGA
COSM4940196	p.Lys107Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000015.10:g.40706272A>T	NCI-TCGA Cosmic
rs1250316987	p.Lys107Thr	missense variant	-	NC_000015.10:g.40706271A>C	gnomAD
rs775210378	p.Glu108Gln	missense variant	-	NC_000015.10:g.40706273G>C	ExAC,gnomAD
rs760517215	p.Lys111Arg	missense variant	-	NC_000015.10:g.40706283A>G	ExAC,gnomAD
rs768873069	p.Leu112Ile	missense variant	-	NC_000015.10:g.40706285C>A	ExAC,gnomAD
NCI-TCGA novel	p.Ile117Thr	missense variant	-	NC_000015.10:g.40709031T>C	NCI-TCGA
NCI-TCGA novel	p.Ser121Tyr	missense variant	-	NC_000015.10:g.40709043C>A	NCI-TCGA
rs143362775	p.Ile122Val	missense variant	-	NC_000015.10:g.40709045A>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1388472001	p.Met125Val	missense variant	-	NC_000015.10:g.40709054A>G	gnomAD
VAR_076870	p.Thr131Pro	Missense	Fanconi anemia, complementation group R (FANCR) [MIM:617244]	-	UniProt
RCV000192086	p.Ile136Phe	missense variant	Mirror movements 2 (MRMV2)	NC_000015.10:g.40709087A>T	ClinVar
rs797044557	p.Ile136Phe	missense variant	-	NC_000015.10:g.40709087A>T	-
rs148345609	p.Thr139Met	missense variant	-	NC_000015.10:g.40709097C>T	ESP,ExAC,TOPMed,gnomAD
rs757033061	p.Ala141Ser	missense variant	-	NC_000015.10:g.40709102G>T	ExAC,gnomAD
rs1259366727	p.Ala141Val	missense variant	-	NC_000015.10:g.40709103C>T	gnomAD
COSM4844703	p.Asp149Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000015.10:g.40718814G>A	NCI-TCGA Cosmic
RCV000014007	p.Arg150Gln	missense variant	Familial cancer of breast	NC_000015.10:g.40718818G>A	ClinVar
rs1359302940	p.Arg150Trp	missense variant	-	NC_000015.10:g.40718817C>T	TOPMed
rs121917739	p.Arg150Gln	missense variant	Breast cancer (BC)	NC_000015.10:g.40718818G>A	UniProt,dbSNP
VAR_010899	p.Arg150Gln	missense variant	Breast cancer (BC)	NC_000015.10:g.40718818G>A	UniProt
rs121917739	p.Arg150Gln	missense variant	-	NC_000015.10:g.40718818G>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1247974770	p.Gly151Cys	missense variant	-	NC_000015.10:g.40718820G>T	gnomAD
rs1015877091	p.Gly151Ala	missense variant	-	NC_000015.10:g.40718821G>C	TOPMed,gnomAD
rs1187974177	p.Gly153Asp	missense variant	-	NC_000015.10:g.40718827G>A	gnomAD
rs781102405	p.Met158Ile	missense variant	-	NC_000015.10:g.40718843G>A	ExAC,gnomAD
rs1440531742	p.Met158Thr	missense variant	-	NC_000015.10:g.40718842T>C	gnomAD
rs752492487	p.Ile160Val	missense variant	-	NC_000015.10:g.40718847A>G	ExAC,TOPMed,gnomAD
rs1304358961	p.Gly164Val	missense variant	-	NC_000015.10:g.40718860G>T	TOPMed,gnomAD
NCI-TCGA novel	p.Glu169Gln	missense variant	-	NC_000015.10:g.40718874G>C	NCI-TCGA
NCI-TCGA novel	p.Arg170Gln	missense variant	-	NC_000015.10:g.40718878G>A	NCI-TCGA
rs1381595625	p.Val174Met	missense variant	-	NC_000015.10:g.40718889G>A	TOPMed,gnomAD
COSM5685612	p.Glu176Gln	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000015.10:g.40718895G>C	NCI-TCGA Cosmic
rs779214128	p.Tyr178Cys	missense variant	-	NC_000015.10:g.40728713A>G	ExAC,TOPMed,gnomAD
rs772233325	p.Gly179Ser	missense variant	-	NC_000015.10:g.40728715G>A	ExAC,gnomAD
rs913824562	p.Gly179Asp	missense variant	-	NC_000015.10:g.40728716G>A	gnomAD
rs1210342872	p.Leu180Val	missense variant	-	NC_000015.10:g.40728718C>G	gnomAD
rs769021479	p.Asp187Gly	missense variant	-	NC_000015.10:g.40728740A>G	ExAC,gnomAD
NCI-TCGA novel	p.Asp187Asn	missense variant	-	NC_000015.10:g.40728739G>A	NCI-TCGA
COSM961290	p.Ala194Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000015.10:g.40728761C>T	NCI-TCGA Cosmic
rs1321607563	p.Thr201Ala	missense variant	-	NC_000015.10:g.40728781A>G	gnomAD
rs1468791932	p.Gln202Arg	missense variant	-	NC_000015.10:g.40728785A>G	TOPMed
rs773933143	p.Gln202Lys	missense variant	-	NC_000015.10:g.40728784C>A	ExAC,gnomAD
rs1555429486	p.Tyr205His	missense variant	-	NC_000015.10:g.40728793T>C	-
RCV000499921	p.Tyr205His	missense variant	-	NC_000015.10:g.40728793T>C	ClinVar
rs759067637	p.Gln206Glu	missense variant	-	NC_000015.10:g.40728796C>G	ExAC,gnomAD
COSM4054411	p.Ala209Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000015.10:g.40728806C>T	NCI-TCGA Cosmic
rs1470830931	p.Ala209Thr	missense variant	-	NC_000015.10:g.40728805G>A	gnomAD
rs1049055390	p.Met210Ile	missense variant	-	NC_000015.10:g.40728810G>C	TOPMed,gnomAD
rs1223584622	p.Val212Ala	missense variant	-	NC_000015.10:g.40728815T>C	TOPMed,gnomAD
COSM3500935	p.Arg215Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000015.10:g.40728824G>A	NCI-TCGA Cosmic
rs776385951	p.Tyr216His	missense variant	-	NC_000015.10:g.40729506T>C	ExAC,gnomAD
COSM433801	p.Leu218Arg	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000015.10:g.40729513T>G	NCI-TCGA Cosmic
rs1010252308	p.Val221Ile	missense variant	-	NC_000015.10:g.40729521G>A	TOPMed,gnomAD
rs1332437837	p.Asp222Gly	missense variant	-	NC_000015.10:g.40729525A>G	gnomAD
rs142701178	p.Ala224Gly	missense variant	-	NC_000015.10:g.40729531C>G	ESP,ExAC,TOPMed,gnomAD
rs1249471221	p.Ala226Thr	missense variant	-	NC_000015.10:g.40729536G>A	TOPMed
rs751662795	p.Ser233Leu	missense variant	-	NC_000015.10:g.40729558C>T	ExAC,TOPMed,gnomAD
rs751662795	p.Ser233Trp	missense variant	-	NC_000015.10:g.40729558C>G	ExAC,TOPMed,gnomAD
rs1196348842	p.Met243Val	missense variant	-	NC_000015.10:g.40729587A>G	gnomAD
NCI-TCGA novel	p.Met243Ile	missense variant	-	NC_000015.10:g.40729589G>A	NCI-TCGA
NCI-TCGA novel	p.Leu245Met	missense variant	-	NC_000015.10:g.40729593T>A	NCI-TCGA
rs1249286135	p.Ala246Ser	missense variant	-	NC_000015.10:g.40729596G>T	gnomAD
rs1329200373	p.Arg247Lys	missense variant	-	NC_000015.10:g.40729600G>A	gnomAD
rs1555429623	p.Arg250Gln	missense variant	Mirror movements 2 (mrmv2)	NC_000015.10:g.40729609G>A	-
RCV000542570	p.Arg250Gln	missense variant	Mirror movements 2 (MRMV2)	NC_000015.10:g.40729609G>A	ClinVar
rs1015133204	p.Leu252Ile	missense variant	-	NC_000015.10:g.40729614C>A	TOPMed
rs376436790	p.Leu253Arg	missense variant	-	NC_000015.10:g.40729618T>G	ESP
RCV000022747	p.Arg254Ter	nonsense	Mirror movements 2 (MRMV2)	NC_000015.10:g.40729620C>T	ClinVar
rs199925463	p.Arg254Ter	stop gained	Mirror movements 2 (mrmv2)	NC_000015.10:g.40729620C>T	TOPMed,gnomAD
rs371150683	p.Arg254Gln	missense variant	-	NC_000015.10:g.40729621G>A	ESP,ExAC,gnomAD
NCI-TCGA novel	p.Arg254Leu	missense variant	-	NC_000015.10:g.40729621G>T	NCI-TCGA
rs374507935	p.Ala256Thr	missense variant	-	NC_000015.10:g.40729626G>A	ESP,ExAC,TOPMed,gnomAD
RCV000626039	p.Glu258Lys	missense variant	Fanconi anemia, complementation group R (FANCR)	NC_000015.10:g.40729632G>A	ClinVar
rs191297852	p.Glu258Ala	missense variant	-	NC_000015.10:g.40729633A>C	1000Genomes,ExAC,TOPMed,gnomAD
rs1555429629	p.Glu258Lys	missense variant	-	NC_000015.10:g.40729632G>A	-
rs1202149010	p.Ile265Met	missense variant	-	NC_000015.10:g.40729873C>G	TOPMed,gnomAD
NCI-TCGA novel	p.Ala271Ser	missense variant	-	NC_000015.10:g.40729889G>T	NCI-TCGA
COSM470584	p.Gln272Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000015.10:g.40729893A>T	NCI-TCGA Cosmic
rs1006483116	p.Val273Ala	missense variant	-	NC_000015.10:g.40729896T>C	TOPMed
rs1372266851	p.Asp274Gly	missense variant	-	NC_000015.10:g.40729899A>G	TOPMed
rs1297305918	p.Ala276Thr	missense variant	-	NC_000015.10:g.40729904G>A	TOPMed
rs532630164	p.Ala277Val	missense variant	-	NC_000015.10:g.40729908C>T	1000Genomes,ExAC,TOPMed,gnomAD
rs760678101	p.Met278Val	missense variant	-	NC_000015.10:g.40729910A>G	ExAC,gnomAD
rs764611353	p.Ala281Ser	missense variant	-	NC_000015.10:g.40729919G>T	ExAC,gnomAD
NCI-TCGA novel	p.Ala281Pro	missense variant	-	NC_000015.10:g.40729919G>C	NCI-TCGA
rs1353527989	p.Pro283Ser	missense variant	-	NC_000015.10:g.40729925C>T	TOPMed,gnomAD
rs754306806	p.Lys284Arg	missense variant	-	NC_000015.10:g.40729929A>G	ExAC,TOPMed,gnomAD
RCV000522398	p.Pro286Leu	missense variant	-	NC_000015.10:g.40729935C>T	ClinVar
RCV000022748	p.Pro286Ter	frameshift	Mirror movements 2 (MRMV2)	NC_000015.10:g.40729933dup	ClinVar
rs1555429670	p.Pro286Leu	missense variant	-	NC_000015.10:g.40729935C>T	-
rs757733241	p.Ile287Thr	missense variant	-	NC_000015.10:g.40729938T>C	ExAC,gnomAD
rs1429537575	p.Ile287Val	missense variant	-	NC_000015.10:g.40729937A>G	TOPMed,gnomAD
RCV000412566	p.Ala293Thr	missense variant	Fanconi anemia, complementation group R (FANCR)	NC_000015.10:g.40729955G>A	ClinVar
RCV000622620	p.Ala293Thr	missense variant	Inborn genetic diseases	NC_000015.10:g.40729955G>A	ClinVar
rs1057519413	p.Ala293Thr	missense variant	-	NC_000015.10:g.40729955G>A	-
NCI-TCGA novel	p.Ser296Leu	missense variant	-	NC_000015.10:g.40729965C>T	NCI-TCGA
rs1386249322	p.Tyr301Cys	missense variant	-	NC_000015.10:g.40731060A>G	TOPMed
rs762285836	p.Gly307Ala	missense variant	-	NC_000015.10:g.40731078G>C	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Gly307Trp	missense variant	-	NC_000015.10:g.40731077G>T	NCI-TCGA
COSM1301079	p.Cys312Tyr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000015.10:g.40731093G>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Cys312Ser	missense variant	-	NC_000015.10:g.40731092T>A	NCI-TCGA
rs767097377	p.Lys313Arg	missense variant	-	NC_000015.10:g.40731096A>G	ExAC,gnomAD
NCI-TCGA novel	p.Asp316Asn	missense variant	-	NC_000015.10:g.40731104G>A	NCI-TCGA
NCI-TCGA novel	p.Glu324Lys	missense variant	-	NC_000015.10:g.40731128G>A	NCI-TCGA
rs374679595	p.Met326Ile	missense variant	-	NC_000015.10:g.40731136G>A	ESP,ExAC,TOPMed,gnomAD
rs755797075	p.Met326Val	missense variant	-	NC_000015.10:g.40731134A>G	ExAC,gnomAD
rs367685211	p.Ala328Ser	missense variant	-	NC_000015.10:g.40731140G>T	ESP,ExAC,TOPMed,gnomAD
rs367685211	p.Ala328Thr	missense variant	-	NC_000015.10:g.40731140G>A	ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Ala328Val	missense variant	-	NC_000015.10:g.40731141C>T	NCI-TCGA
rs1263727210	p.Asp332His	missense variant	-	NC_000015.10:g.40731152G>C	TOPMed
NCI-TCGA novel	p.Asp332Asn	missense variant	-	NC_000015.10:g.40731152G>A	NCI-TCGA
rs1391217140	p.Asp339His	missense variant	-	NC_000015.10:g.40731173G>C	gnomAD
rs1484599682	p.Ter340Arg	stop lost	-	NC_000015.10:g.40731176T>C	TOPMed

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0001418	Adenocarcinoma	group	LHGDN
C0001430	Adenoma	group	BEFREE
C0002793	Anaplasia	disease	BEFREE
C0003466	Anus, Imperforate	disease	HPO
C0005684	Malignant neoplasm of urinary bladder	disease	BEFREE
C0005695	Bladder Neoplasm	group	BEFREE
C0005859	Bloom Syndrome	disease	BEFREE
C0006111	Brain Diseases	group	BEFREE
C0006118	Brain Neoplasms	group	BEFREE
C0006142	Malignant neoplasm of breast	disease	BEFREE;CTD_human;UNIPROT
C0006826	Malignant Neoplasms	group	BEFREE
C0007102	Malignant tumor of colon	disease	BEFREE
C0007113	Rectal Carcinoma	disease	BEFREE
C0007115	Malignant neoplasm of thyroid	disease	BEFREE
C0007120	Bronchioloalveolar Adenocarcinoma	disease	BEFREE
C0007131	Non-Small Cell Lung Carcinoma	disease	BEFREE
C0007137	Squamous cell carcinoma	disease	BEFREE
C0007758	Cerebellar Ataxia	phenotype	BEFREE
C0007847	Malignant tumor of cervix	disease	BEFREE
C0008073	Developmental Disabilities	group	BEFREE
C0008626	Congenital chromosomal disease	group	BEFREE
C0009324	Ulcerative Colitis	disease	BEFREE
C0010674	Cystic Fibrosis	disease	BEFREE
C0011168	Deglutition Disorders	group	BEFREE
C0012546	Diphtheria	disease	BEFREE
C0014522	Epidermodysplasia Verruciformis	disease	BEFREE
C0014859	Esophageal Neoplasms	group	BEFREE
C0015625	Fanconi Anemia	disease	BEFREE;ORPHANET
C0016057	Fibrosarcoma	disease	BEFREE
C0016382	Flushing	phenotype	BEFREE
C0017636	Glioblastoma	disease	BEFREE
C0017638	Glioma	disease	BEFREE
C0018671	Head and Neck Neoplasms	group	CTD_human;LHGDN
C0018675	Head Neoplasms	group	CTD_human
C0019348	Herpes Simplex Infections	group	BEFREE
C0020255	Hydrocephalus	disease	HPO
C0020538	Hypertensive disease	group	RGD
C0023418	leukemia	disease	BEFREE;LHGDN
C0023434	Chronic Lymphocytic Leukemia	disease	BEFREE
C0023452	Childhood Acute Lymphoblastic Leukemia	disease	BEFREE
C0023467	Leukemia, Myelocytic, Acute	disease	BEFREE
C0023473	Myeloid Leukemia, Chronic	disease	BEFREE
C0023524	Leukoencephalopathy, Progressive Multifocal	disease	BEFREE
C0023530	Leukopenia	disease	HPO
C0024121	Lung Neoplasms	group	LHGDN
C0024198	Lyme Disease	disease	BEFREE
C0024299	Lymphoma	group	BEFREE
C0024623	Malignant neoplasm of stomach	disease	BEFREE
C0025149	Medulloblastoma	disease	BEFREE
C0025362	Mental Retardation	disease	HPO
C0026650	Movement Disorders	group	BEFREE
C0026764	Multiple Myeloma	disease	BEFREE
C0027533	Neck Neoplasms	group	CTD_human
C0027627	Neoplasm Metastasis	phenotype	BEFREE
C0029463	Osteosarcoma	disease	BEFREE
C0029925	Ovarian Carcinoma	disease	BEFREE
C0030297	Pancreatic Neoplasm	disease	RGD
C0030521	Parathyroid Neoplasms	group	BEFREE
C0033141	Cardiomyopathies, Primary	group	RGD
C0033300	Progeria	disease	BEFREE
C0033578	Prostatic Neoplasms	group	BEFREE
C0036529	Myocardial Diseases, Secondary	group	RGD
C0036572	Seizures	phenotype	BEFREE
C0037932	Curvature of spine	phenotype	HPO
C0040034	Thrombocytopenia	phenotype	HPO
C0043119	Werner Syndrome	disease	BEFREE
C0085584	Encephalopathies	group	BEFREE
C0085669	Acute leukemia	disease	BEFREE
C0149925	Small cell carcinoma of lung	disease	BEFREE
C0151686	Growth retardation	phenotype	HPO
C0152018	Esophageal carcinoma	disease	BEFREE
C0153458	malignant neoplasm of head of pancreas	disease	RGD
C0153459	Malignant neoplasm of body of pancreas	disease	RGD
C0153460	Malignant neoplasm of tail of pancreas	disease	RGD
C0153463	Malignant neoplasm of other specified sites of pancreas	disease	RGD
C0153676	Secondary malignant neoplasm of lung	disease	BEFREE
C0178874	Tumor Progression	phenotype	BEFREE
C0206704	Carcinoma, Large Cell	disease	BEFREE
C0220633	Uveal melanoma	disease	BEFREE
C0220650	Metastatic malignant neoplasm to brain	disease	BEFREE
C0221002	Hyperparathyroidism, Primary	disease	BEFREE
C0231341	Premature aging syndrome	disease	BEFREE
C0235974	Pancreatic carcinoma	disease	BEFREE
C0238198	Gastrointestinal Stromal Tumors	group	BEFREE
C0242379	Malignant neoplasm of lung	disease	BEFREE
C0262587	Parathyroid Adenoma	disease	BEFREE
C0265783	Congenital hypoplasia of lung	disease	BEFREE
C0268138	Xeroderma Pigmentosum, Complementation Group D	disease	BEFREE
C0272027	Pyridoxine-responsive sideroblastic anemia	disease	HPO
C0278996	Malignant Head and Neck Neoplasm	disease	BEFREE;CTD_human
C0281361	Adenocarcinoma of pancreas	disease	BEFREE
C0281842	Abnormality of the fallopian tube	phenotype	HPO
C0302592	Cervix carcinoma	disease	BEFREE
C0334634	Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse	disease	BEFREE
C0342510	Ovarian dysgenesis	disease	BEFREE
C0345905	Intrahepatic Cholangiocarcinoma	disease	BEFREE
C0346153	Breast Cancer, Familial	disease	BEFREE;CLINVAR;UNIPROT
C0346429	Multiple malignancy	phenotype	BEFREE
C0346647	Malignant neoplasm of pancreas	disease	BEFREE
C0346976	Secondary malignant neoplasm of pancreas	disease	BEFREE
C0349588	Short stature	phenotype	HPO
C0376358	Malignant neoplasm of prostate	disease	BEFREE
C0376628	Chromosome Breakage	phenotype	HPO
C0392386	Decreased platelet count	phenotype	HPO
C0423112	Short palpebral fissure	phenotype	HPO
C0423903	Low intelligence	phenotype	HPO
C0424295	Hyperactive behavior	phenotype	BEFREE
C0424688	Small head	phenotype	HPO
C0454455	Mirror movements disorder	disease	BEFREE;HPO
C0456070	Growth delay	phenotype	HPO
C0546837	Malignant neoplasm of esophagus	disease	BEFREE
C0549473	Thyroid carcinoma	disease	BEFREE
C0557874	Global developmental delay	disease	HPO
C0585442	Osteosarcoma of bone	disease	BEFREE
C0596263	Carcinogenesis	phenotype	BEFREE
C0596321	Chemical Carcinogenesis	phenotype	BEFREE
C0598935	Tumor Initiation	phenotype	BEFREE
C0600139	Prostate carcinoma	disease	BEFREE
C0677776	Hereditary Breast and Ovarian Cancer Syndrome	disease	ORPHANET
C0678222	Breast Carcinoma	disease	BEFREE;CTD_human;HPO
C0684249	Carcinoma of lung	disease	BEFREE
C0686619	Secondary malignant neoplasm of lymph node	disease	BEFREE
C0699790	Colon Carcinoma	disease	BEFREE
C0699791	Stomach Carcinoma	disease	BEFREE
C0699885	Carcinoma of bladder	disease	BEFREE
C0700208	Acquired scoliosis	phenotype	HPO
C0746787	Cancer of Neck	disease	CTD_human
C0751177	Cancer of Head	disease	CTD_human
C0850666	Infection caused by Helicobacter pylori	disease	BEFREE
C0855095	Small Lymphocytic Lymphoma	disease	BEFREE
C0878544	Cardiomyopathies	group	BEFREE;RGD
C0878787	Growth failure	phenotype	HPO
C0887900	Upper Aerodigestive Tract Neoplasms	group	CTD_human
C0917816	Mental deficiency	disease	HPO
C0919267	ovarian neoplasm	disease	HPO
C0950123	Genetic Diseases, Inborn	group	CLINVAR
C1134719	Invasive Ductal Breast Carcinoma	disease	BEFREE
C1140680	Malignant neoplasm of ovary	disease	BEFREE;HPO
C1168401	Squamous cell carcinoma of the head and neck	disease	BEFREE
C1257931	Mammary Neoplasms, Human	group	CTD_human
C1261473	Sarcoma	group	BEFREE;LHGDN
C1306459	Primary malignant neoplasm	group	BEFREE
C1306460	Primary malignant neoplasm of lung	disease	BEFREE
C1332460	Barrett's Adenocarcinoma	disease	BEFREE
C1333600	Hereditary Malignant Neoplasm	group	BEFREE
C1336076	Sporadic Breast Carcinoma	disease	BEFREE
C1336735	Treatment related acute myeloid leukaemia	disease	BEFREE
C1458155	Mammary Neoplasms	group	BEFREE;CTD_human;LHGDN
C1514428	Primary peritoneal carcinoma	disease	HPO
C1621958	Glioblastoma Multiforme	disease	BEFREE
C1836735	hypopigmented skin patch	phenotype	HPO
C1837385	Poor growth	phenotype	HPO
C1843367	Poor school performance	phenotype	HPO
C1857276	Trichohepatoenteric Syndrome	disease	BEFREE
C1860236	Irregular hyperpigmentation	phenotype	HPO
C1861906	Breast Cancer, Familial Male	disease	UNIPROT
C1864897	Cognitive delay	phenotype	HPO
C2239176	Liver carcinoma	disease	BEFREE
C2749463	Aplasia/Hypoplasia of the radius	phenotype	HPO
C2931822	Nasopharyngeal carcinoma	disease	BEFREE
C3160738	FANCONI ANEMIA, COMPLEMENTATION GROUP D2	disease	BEFREE
C3281089	MIRROR MOVEMENTS 2	disease	CLINVAR;CTD_human
C3463824	MYELODYSPLASTIC SYNDROME	group	BEFREE
C3469521	FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder)	disease	BEFREE
C3539878	Triple Negative Breast Neoplasms	disease	BEFREE
C3552463	Very poor growth	phenotype	HPO
C3714636	Pneumonitis	disease	BEFREE
C3714756	Intellectual Disability	group	HPO
C3888194	MIXED LINEAGE LEUKEMIA	disease	BEFREE
C4020875	Mental and motor retardation	phenotype	HPO
C4020876	Dull intelligence	phenotype	HPO
C4024780	Almond-shaped palpebral fissure	phenotype	HPO
C4048328	cervical cancer	disease	BEFREE
C4284093	FANCONI ANEMIA, COMPLEMENTATION GROUP R	disease	CLINVAR;CTD_human;UNIPROT

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0000150	recombinase activity	IBA
GO:0003682	chromatin binding	IDA
GO:0003690	double-stranded DNA binding	IBA
GO:0003690	double-stranded DNA binding	IMP
GO:0003690	double-stranded DNA binding	IDA
GO:0003697	single-stranded DNA binding	IBA
GO:0003697	single-stranded DNA binding	IMP
GO:0003697	single-stranded DNA binding	IDA
GO:0005515	protein binding	IPI
GO:0005524	ATP binding	IDA
GO:0008022	protein C-terminus binding	IPI
GO:0008094	DNA-dependent ATPase activity	IBA
GO:0017116	single-stranded DNA helicase activity	IMP
GO:0017116	single-stranded DNA helicase activity	IDA
GO:0019899	enzyme binding	IPI
GO:0042802	identical protein binding	IPI
GO:0070182	DNA polymerase binding	IPI

GO:Biological Process

GO ID	GO Term	Evidence
GO:0000722	telomere maintenance via recombination	ISS
GO:0000724	double-strand break repair via homologous recombination	TAS
GO:0000724	double-strand break repair via homologous recombination	IDA
GO:0000724	double-strand break repair via homologous recombination	IMP
GO:0000730	DNA recombinase assembly	IBA
GO:0000730	DNA recombinase assembly	IMP
GO:0001932	regulation of protein phosphorylation	IEA
GO:0006268	DNA unwinding involved in DNA replication	IDA
GO:0006281	DNA repair	TAS
GO:0006310	DNA recombination	TAS
GO:0006312	mitotic recombination	IBA
GO:0006974	cellular response to DNA damage stimulus	IDA
GO:0006974	cellular response to DNA damage stimulus	IMP
GO:0007131	reciprocal meiotic recombination	IBA
GO:0010165	response to X-ray	IEA
GO:0010212	response to ionizing radiation	IBA
GO:0010569	regulation of double-strand break repair via homologous recombination	IDA
GO:0010833	telomere maintenance via telomere lengthening	ISS
GO:0031297	replication fork processing	IMP
GO:0031297	replication fork processing	IDA
GO:0036297	interstrand cross-link repair	IMP
GO:0042148	strand invasion	IBA
GO:0051106	positive regulation of DNA ligation	IDA
GO:0051321	meiotic cell cycle	ISS
GO:0070192	chromosome organization involved in meiotic cell cycle	IBA
GO:0070317	negative regulation of G0 to G1 transition	TAS
GO:0071479	cellular response to ionizing radiation	IDA
GO:0071480	cellular response to gamma radiation	IEA
GO:0072711	cellular response to hydroxyurea	IEA
GO:0072719	cellular response to cisplatin	IEA
GO:0072757	cellular response to camptothecin	IDA
GO:1904631	response to glucoside	IEA
GO:1990414	replication-born double-strand break repair via sister chromatid exchange	IEA
GO:1990426	mitotic recombination-dependent replication fork processing	IEA

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0000228	nuclear chromosome	IDA
GO:0000784	nuclear chromosome, telomeric region	IDA
GO:0000785	chromatin	IDA
GO:0000790	nuclear chromatin	IDA
GO:0000793	condensed chromosome	ISS
GO:0000794	condensed nuclear chromosome	ISS
GO:0000794	condensed nuclear chromosome	IBA
GO:0000800	lateral element	IDA
GO:0005634	nucleus	ISS
GO:0005634	nucleus	IDA
GO:0005654	nucleoplasm	TAS
GO:0005737	cytoplasm	IDA
GO:0005739	mitochondrion	IDA
GO:0005759	mitochondrial matrix	IEA
GO:0005815	microtubule organizing center	IEA
GO:0016605	PML body	IDA
GO:0032991	protein-containing complex	IDA
GO:0035861	site of double-strand break	IDA
GO:0048471	perinuclear region of cytoplasm	IDA

Reactome Pathway

Reactome ID	Reactome Term	Evidence
R-HSA-1474165	Reproduction	IEA
R-HSA-1500620	Meiosis	IEA
R-HSA-1640170	Cell Cycle	IEA
R-HSA-212436	Generic Transcription Pathway	TAS
R-HSA-5685938	HDR through Single Strand Annealing (SSA)	TAS
R-HSA-5685942	HDR through Homologous Recombination (HRR)	TAS
R-HSA-5693532	DNA Double-Strand Break Repair	TAS
R-HSA-5693537	Resolution of D-Loop Structures	TAS
R-HSA-5693538	Homology Directed Repair	TAS
R-HSA-5693554	Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	TAS
R-HSA-5693567	HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)	TAS
R-HSA-5693568	Resolution of D-loop Structures through Holliday Junction Intermediates	TAS
R-HSA-5693579	Homologous DNA Pairing and Strand Exchange	TAS
R-HSA-5693616	Presynaptic phase of homologous DNA pairing and strand exchange	TAS
R-HSA-73857	RNA Polymerase II Transcription	TAS
R-HSA-73894	DNA Repair	TAS
R-HSA-74160	Gene expression (Transcription)	TAS
R-HSA-8953750	Transcriptional Regulation by E2F6	TAS
R-HSA-912446	Meiotic recombination	IEA

Drugs and compounds information

ID	Drug Name	Action	PubMed
C026486	1,2,5,6-dibenzanthracene	1,2,5,6-dibenzanthracene results in increased expression of RAD51 mRNA	26377693
C517232	1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane	1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane results in increased expression of RAD51 mRNA	23958786
C582286	1-(3-((2-(dimethylamino)ethyl)carbamoyl)phenyl)-3-(4-(bis(2-chloroethyl)amino)phenyl)urea	RAD51 mutant form results in increased susceptibility to 1-(3-((2-(dimethylamino)ethyl)carbamoyl)phenyl)-3-(4-(bis(2-chloroethyl)amino)phenyl)urea	26208482
C028474	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Pregnenolone Carbonitrile] results in increased expression of RAD51 mRNA	23626729
C028474	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of RAD51 mRNA	22698814; 23626729; 28903501;
D015058	1-Naphthylisothiocyanate	1-Naphthylisothiocyanate results in increased expression of RAD51 mRNA	30723492
C029790	2,2',3',4,4',5-hexachlorobiphenyl	[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of RAD51 mRNA	25510870
C511295	2,2',4,4'-tetrabromodiphenyl ether	2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of RAD51 mRNA	20566336
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [ochratoxin A results in decreased expression of RAD51]	24525463
C029497	2,3-bis(3'-hydroxybenzyl)butyrolactone	[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAD51 mRNA	19167446
C081766	2,4,4'-trichlorobiphenyl	[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of RAD51 mRNA	25510870
C014024	2,4,5,2',4',5'-hexachlorobiphenyl	[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of RAD51 mRNA	25510870
C009828	2,4,5,2',5'-pentachlorobiphenyl	[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of RAD51 mRNA	25510870
C010914	2,4-diaminotoluene	2,4-diaminotoluene results in increased expression of RAD51 mRNA	20713471
C009407	2,5,2',5'-tetrachlorobiphenyl	[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of RAD51 mRNA	25510870
C006551	2-amino-2-methyl-1-propanol	2-amino-2-methyl-1-propanol results in increased expression of RAD51 mRNA	25088246
C036990	2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline	[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of RAD51 mRNA	23681119
C479235	2-(morpholin-4-yl)benzo(h)chromen-4-one	[Irinotecan co-treated with 2-(morpholin-4-yl)benzo(h)chromen-4-one] results in increased expression of RAD51 protein	21221710
C471109	4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline	4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline results in decreased expression of RAD51 mRNA	19934314
D017878	4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid	4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid results in decreased activity of RAD51 protein	23589568
D017878	4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid	[4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid results in decreased activity of RAD51 protein] which results in increased activity of AICDA protein	23589568
C006757	4-biphenylamine	4-biphenylamine results in decreased expression of RAD51 mRNA	24857880
C027576	4-hydroxy-2-nonenal	4-hydroxy-2-nonenal results in decreased expression of RAD51 mRNA	19191707
C027576	4-hydroxy-2-nonenal	4-hydroxy-2-nonenal results in increased expression of RAD51 mRNA	19191707
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of RAD51 mRNA	20382639
D015127	9,10-Dimethyl-1,2-benzanthracene	9,10-Dimethyl-1,2-benzanthracene results in increased expression of RAD51 mRNA	25448685
D015127	9,10-Dimethyl-1,2-benzanthracene	9,10-Dimethyl-1,2-benzanthracene results in increased expression of RAD51 protein	25448685
D015127	9,10-Dimethyl-1,2-benzanthracene	A gene mutant form affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of RAD51 protein]	25448685
D015127	9,10-Dimethyl-1,2-benzanthracene	A gene mutant form inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of RAD51 mRNA]	25448685
D015127	9,10-Dimethyl-1,2-benzanthracene	9,10-Dimethyl-1,2-benzanthracene results in increased expression of RAD51 mRNA	23969067
C496492	abrine	abrine results in decreased expression of RAD51 mRNA	31054353
D000082	Acetaminophen	Acetaminophen results in increased expression of RAD51 mRNA	22230336
C063261	acetylleucyl-leucyl-norleucinal	acetylleucyl-leucyl-norleucinal inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]]	21810436
C063261	acetylleucyl-leucyl-norleucinal	acetylleucyl-leucyl-norleucinal inhibits the reaction [[Mitomycin co-treated with Curcumin] results in decreased expression of RAD51 mRNA]	21810436
D020106	Acrylamide	Acrylamide results in increased expression of RAD51 mRNA	28959563
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of RAD51 mRNA	29445054
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of RAD51 mRNA	23630614; 25378103;
C000593263	afuresertib	afuresertib results in decreased expression of RAD51 mRNA	28960945
D000393	Air Pollutants	Air Pollutants results in increased expression of RAD51 protein	28389379
C059765	amphotericin B, deoxycholate drug combination	amphotericin B, deoxycholate drug combination results in increased expression of RAD51 mRNA	22863853
D000677	Amsacrine	RAD51 protein affects the susceptibility to Amsacrine	16600179
D001151	Arsenic	Arsenic affects the methylation of RAD51 gene	25304211
C015001	arsenite	arsenite results in decreased expression of RAD51 mRNA	18929588
D017638	Asbestos, Crocidolite	Asbestos, Crocidolite results in decreased expression of RAD51 mRNA	29523930
C547126	AZM551248	AZM551248 results in increased expression of RAD51 mRNA	22323515
C030935	benz(a)anthracene	[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RAD51 mRNA	27858113
D001554	Benzene	Benzene results in decreased expression of RAD51 mRNA	18724895
D001554	Benzene	Benzene results in increased expression of RAD51 mRNA	15342939
D001554	Benzene	TRP53 protein affects the reaction [Benzene results in decreased expression of RAD51 mRNA]	12928149
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of RAD51 mRNA	25612249
D001564	Benzo(a)pyrene	Benzo(a)pyrene affects the methylation of RAD51 intron	30157460
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of RAD51 mRNA	20064835
D001564	Benzo(a)pyrene	[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RAD51 mRNA	27858113
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of RAD51 mRNA	20713471
C006703	benzo(b)fluoranthene	[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RAD51 mRNA	27858113
C006703	benzo(b)fluoranthene	benzo(b)fluoranthene results in increased expression of RAD51 mRNA	26377693
C026487	benzo(e)pyrene	benzo(e)pyrene results in decreased methylation of RAD51 intron	30157460
C072553	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]]	21810436
C072553	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Mitomycin co-treated with Curcumin] results in decreased expression of RAD51 mRNA]	21810436
C006780	bisphenol A	bisphenol A affects the expression of RAD51 mRNA	21786754
C006780	bisphenol A	bisphenol A results in decreased expression of RAD51 mRNA	29275510
C006780	bisphenol A	bisphenol A results in increased expression of RAD51 mRNA	16474171; 22576693;
C006780	bisphenol A	bisphenol A results in decreased expression of RAD51 mRNA	25181051
D000069286	Bortezomib	Bortezomib results in decreased expression of RAD51 mRNA	21917757
C016274	bromoacetate	bromoacetate results in increased expression of RAD51 mRNA	19753638
D002066	Busulfan	Busulfan results in decreased expression of RAD51 mRNA	15388331
C584509	C646 compound	C646 compound results in decreased expression of RAD51 mRNA	23698071
D002104	Cadmium	Cadmium results in decreased expression of RAD51 mRNA	18522720
D019256	Cadmium Chloride	Cadmium Chloride results in decreased expression of RAD51 mRNA	25456234
D019256	Cadmium Chloride	Cadmium Chloride results in increased expression of RAD51 mRNA	16799861
D019256	Cadmium Chloride	Cadmium Chloride results in increased expression of RAD51 mRNA	12160620
D019256	Cadmium Chloride	Cadmium Chloride results in decreased expression of RAD51 mRNA	25993096
D002117	Calcitriol	Calcitriol results in decreased expression of RAD51 mRNA	21592394
D002117	Calcitriol	[Testosterone co-treated with Calcitriol] results in decreased expression of RAD51 mRNA	21592394
D002166	Camptothecin	Camptothecin results in decreased expression of RAD51 mRNA	10344722; 24792648;
D002166	Camptothecin	Camptothecin results in decreased expression of RAD51 protein	10344722
D002220	Carbamazepine	Carbamazepine affects the expression of RAD51 mRNA	24752500
D002251	Carbon Tetrachloride	Carbon Tetrachloride affects the expression of RAD51 mRNA	17484886
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of RAD51 mRNA	27339419
D002330	Carmustine	Carmustine results in decreased expression of RAD51 mRNA	15980968
D002699	Chlorambucil	Chlorambucil results in increased expression of RAD51 protein	10473103
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of RAD51	20938992
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of RAD51 gene	20938992
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of RAD51 mRNA	20938992
D002857	Chromium	Chromium results in increased expression of RAD51 mRNA	18084045
C074702	chromium hexavalent ion	chromium hexavalent ion affects the phosphorylation of and affects the expression of RAD51 protein	25173789
C074702	chromium hexavalent ion	chromium hexavalent ion results in decreased expression of and results in decreased localization of RAD51 protein	27449664
C074702	chromium hexavalent ion	chromium hexavalent ion results in decreased expression of RAD51 mRNA	30690063
C031180	chrysene	[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RAD51 mRNA	27858113
D002945	Cisplatin	Cisplatin results in increased expression of RAD51 mRNA	27594783
D002945	Cisplatin	Cisplatin results in increased expression of RAD51 protein	26723870
D002945	Cisplatin	NQO1 protein affects the reaction [Cisplatin results in increased expression of RAD51 protein]	26723870
D002945	Cisplatin	Cisplatin results in decreased expression of RAD51 mRNA	22023808
D003033	Coal Tar	Coal Tar results in decreased expression of RAD51 mRNA	27858113
D003300	Copper	[NSC 689534 binds to Copper] which results in decreased expression of RAD51 mRNA	20971185
D003300	Copper	Copper results in increased expression of RAD51 mRNA	17205981
D019327	Copper Sulfate	Copper Sulfate results in decreased expression of RAD51 mRNA	19549813
D003375	Coumestrol	[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAD51 mRNA	19167446
D003375	Coumestrol	[Coumestrol co-treated with Resveratrol] results in increased expression of RAD51 mRNA	19167446
D003375	Coumestrol	Coumestrol results in increased expression of RAD51 mRNA	19167446
C408982	CPG-oligonucleotide	CPG-oligonucleotide results in decreased expression of RAD51 protein	21878529
C408982	CPG-oligonucleotide	CPG-oligonucleotide results in increased expression of RAD51 mRNA	21878529
D003474	Curcumin	acetylleucyl-leucyl-norleucinal inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]]	21810436
D003474	Curcumin	acetylleucyl-leucyl-norleucinal inhibits the reaction [[Mitomycin co-treated with Curcumin] results in decreased expression of RAD51 mRNA]	21810436
D003474	Curcumin	benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]]	21810436
D003474	Curcumin	benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Mitomycin co-treated with Curcumin] results in decreased expression of RAD51 mRNA]	21810436
D003474	Curcumin	Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]	21810436
D003474	Curcumin	MAP2K1 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]]	21810436
D003474	Curcumin	MAP2K2 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]]	21810436
D003474	Curcumin	[Mitomycin co-treated with Curcumin] results in decreased expression of RAD51 mRNA	21810436
D003474	Curcumin	RAD51 results in decreased susceptibility to [Curcumin co-treated with Mitomycin]	21810436
D003474	Curcumin	U 0126 promotes the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]]	21810436
D003474	Curcumin	U 0126 promotes the reaction [[Mitomycin co-treated with Curcumin] results in decreased expression of RAD51 mRNA]	21810436
D003520	Cyclophosphamide	Cyclophosphamide results in decreased expression of RAD51 mRNA	21041162
D003520	Cyclophosphamide	Cyclophosphamide results in increased expression of RAD51 mRNA	11599041
D016572	Cyclosporine	Cyclosporine results in decreased expression of RAD51 mRNA	25562108
C089595	cylindrospermopsin	cylindrospermopsin results in decreased expression of RAD51 mRNA	23726867
C017160	cypermethrin	cypermethrin results in increased expression of RAD51 mRNA	21142847
D003561	Cytarabine	Cytarabine results in increased expression of RAD51 mRNA	19194470
D003609	Dactinomycin	Dactinomycin results in decreased expression of RAD51 mRNA	27989139
D003609	Dactinomycin	tetrachlorobenzoquinone promotes the reaction [Dactinomycin results in decreased expression of RAD51 mRNA]	27989139
D000069439	Dasatinib	Dasatinib results in decreased expression of RAD51 mRNA	20579391
D000077209	Decitabine	Decitabine affects the localization of RAD51 protein modified form	17991895
D003703	Demecolcine	Demecolcine affects the localization of RAD51 protein	9885240
D003907	Dexamethasone	Dexamethasone results in decreased expression of RAD51 mRNA	21041162
D064730	Dexrazoxane	[Dexrazoxane co-treated with Idarubicin] results in increased expression of RAD51 mRNA	28973540
C023614	dibenzofuran	dibenzofuran analog results in decreased expression of RAD51 mRNA	20566336
D003999	Dichloroacetic Acid	Dichloroacetic Acid results in increased expression of RAD51 mRNA	28962523
D004008	Diclofenac	Diclofenac affects the expression of RAD51 mRNA	24752500
D004008	Diclofenac	Diclofenac results in increased expression of RAD51 mRNA	30723492
C036042	dicyclohexyl phthalate	dicyclohexyl phthalate results in increased expression of RAD51 mRNA	26924002
D004052	Diethylnitrosamine	[Diethylnitrosamine co-treated with Phenobarbital] results in increased expression of RAD51 mRNA	24535843
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of RAD51 mRNA	17854601
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of RAD51 protein	18506893
D004052	Diethylnitrosamine	RB1 protein inhibits the reaction [Diethylnitrosamine results in increased expression of RAD51 mRNA]	17854601
D004054	Diethylstilbestrol	Diethylstilbestrol results in decreased expression of RAD51 mRNA	21041162
D004126	Dimethylformamide	Dimethylformamide results in increased expression of RAD51 mRNA	26387567
D004126	Dimethylformamide	Dimethylformamide results in increased expression of RAD51 protein	26387567
C024629	dimethyl phthalate	dimethyl phthalate results in increased expression of RAD51 mRNA	26924002
C553669	dinaciclib	dinaciclib results in decreased expression of RAD51 protein	27880910
D004317	Doxorubicin	Doxorubicin affects the expression of RAD51 protein	17351394
D004317	Doxorubicin	Doxorubicin results in decreased expression of RAD51 mRNA	10344722
D004317	Doxorubicin	Doxorubicin results in decreased expression of RAD51 protein	10344722
D004317	Doxorubicin	Doxorubicin results in decreased expression of RAD51 mRNA	27181935
D004317	Doxorubicin	Doxorubicin results in decreased expression of RAD51 protein	24902966
D004317	Doxorubicin	Fungal Polysaccharides inhibits the reaction [Doxorubicin results in decreased expression of RAD51 mRNA]	27181935
D004317	Doxorubicin	Quercetin inhibits the reaction [Doxorubicin results in decreased expression of RAD51 protein]	24902966
D004726	Endosulfan	[Endosulfan co-treated with Tetrachlorodibenzodioxin] results in increased expression of RAD51 mRNA	26159488
D004726	Endosulfan	Endosulfan results in increased expression of RAD51 mRNA	29391264
C045651	epigallocatechin gallate	[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAD51 mRNA	22079256
D000069347	Erlotinib Hydrochloride	[Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD51 protein	23548265
D004918	Erythromycin Estolate	Erythromycin Estolate results in decreased expression of RAD51 mRNA	24412560
D004918	Erythromycin Estolate	Erythromycin Estolate results in increased expression of RAD51 mRNA	24412560
D004958	Estradiol	Estradiol results in increased expression of RAD51 mRNA	16474171; 18310284;
C007633	estragole	estragole results in increased expression of RAD51 protein	29054680
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of RAD51 mRNA	23129252
D005020	Ethyl Methanesulfonate	Ethyl Methanesulfonate affects the expression of RAD51 mRNA	25612249
D005047	Etoposide	Etoposide affects the localization of RAD51 protein	9885240
D017313	Fenretinide	Fenretinide results in increased expression of RAD51 mRNA	28973697
C024352	fludarabine	[LAQ824 co-treated with fludarabine] results in decreased expression of RAD51 mRNA	18852132
C012976	flumequine	[flumequine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of RAD51 mRNA	23681119
D005485	Flutamide	Flutamide results in decreased expression of RAD51 mRNA	21126777
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of RAD51	20938992
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of RAD51 gene	20938992
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of RAD51 mRNA	20938992
D000077267	Fulvestrant	[Fulvestrant co-treated with Sirolimus] results in decreased expression of RAD51 mRNA	19016759
D000077267	Fulvestrant	Fulvestrant results in decreased expression of RAD51 mRNA	19016759
D062610	Fungal Polysaccharides	Fungal Polysaccharides inhibits the reaction [Doxorubicin results in decreased expression of RAD51 mRNA]	27181935
C039281	furan	furan results in decreased expression of RAD51 mRNA	22507866
C039281	furan	furan results in increased expression of RAD51 mRNA	25539665
D019833	Genistein	Genistein results in increased expression of RAD51 mRNA	16474171
C007836	geraniol	geraniol results in decreased expression of RAD51 mRNA	27683099
C000593030	GSK-J4	GSK-J4 results in decreased expression of RAD51 mRNA	29301935
C575866	IC486241	[Irinotecan co-treated with IC486241] results in increased expression of RAD51 protein	21221710
D015255	Idarubicin	[Dexrazoxane co-treated with Idarubicin] results in increased expression of RAD51 mRNA	28973540
C545476	incobotulinumtoxinA	incobotulinumtoxinA results in decreased expression of RAD51 mRNA	29522793
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of RAD51 mRNA	25613284
D000077146	Irinotecan	[Irinotecan co-treated with 2-(morpholin-4-yl)benzo(h)chromen-4-one] results in increased expression of RAD51 protein	21221710
D000077146	Irinotecan	[Irinotecan co-treated with IC486241] results in increased expression of RAD51 protein	21221710
D000077146	Irinotecan	Irinotecan results in increased expression of RAD51 protein	21221710
C544151	jinfukang	jinfukang results in increased expression of RAD51 mRNA	27392435
C561695	(+)-JQ1 compound	[BCL2L1 protein co-treated with RAD51 protein] inhibits the reaction [GNAQ gene mutant form results in increased susceptibility to (+)-JQ1 compound]	26397223
C561695	(+)-JQ1 compound	[BCL2L1 protein co-treated with RAD51 protein] inhibits the reaction [[GNAQ gene mutant form results in increased susceptibility to (+)-JQ1 compound] which results in increased cleavage of PARP1 protein]	26397223
C561695	(+)-JQ1 compound	[GNAQ gene mutant form results in increased susceptibility to (+)-JQ1 compound] which results in decreased expression of RAD51 mRNA	26397223
C561695	(+)-JQ1 compound	[GNAQ gene mutant form results in increased susceptibility to (+)-JQ1 compound] which results in decreased expression of RAD51 protein	26397223
C561695	(+)-JQ1 compound	(+)-JQ1 compound inhibits the reaction [GNAQ gene mutant form promotes the reaction [BRD4 protein binds to RAD51 promoter]]	26397223
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of RAD51 mRNA	24796395
C410337	K 7174	K 7174 results in decreased expression of RAD51 mRNA	24086573
C477361	LAQ824	[LAQ824 co-treated with fludarabine] results in decreased expression of RAD51 mRNA	18852132
D007840	Latex	Latex analog results in increased expression of RAD51 mRNA	24768652
D000077339	Leflunomide	Leflunomide results in decreased expression of RAD51 mRNA	28988120; 29427785;
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased expression of RAD51 mRNA	12057914
D008154	Lucanthone	Lucanthone results in decreased expression of RAD51 mRNA	21148553
D008466	Mechlorethamine	Mechlorethamine results in increased expression of RAD51 protein	25891025
D008701	Methapyrilene	Methapyrilene results in decreased methylation of RAD51 intron	30157460
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of RAD51	20938992
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of RAD51 gene	20938992
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of RAD51 mRNA	20938992
D008731	Methoxychlor	Methoxychlor results in decreased expression of RAD51 mRNA	21276474
D008748	Methylcholanthrene	Methylcholanthrene results in increased expression of RAD51 mRNA	20713471
D008767	Methylmercury Compounds	Methylmercury Compounds results in decreased expression of RAD51 mRNA	15984772
D008767	Methylmercury Compounds	Methylmercury Compounds results in increased expression of RAD51 mRNA	15984772
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in increased expression of RAD51 protein	24743697
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in increased expression of RAD51 mRNA	23649840
D016685	Mitomycin	acetylleucyl-leucyl-norleucinal inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]]	21810436
D016685	Mitomycin	acetylleucyl-leucyl-norleucinal inhibits the reaction [[Mitomycin co-treated with Curcumin] results in decreased expression of RAD51 mRNA]	21810436
D016685	Mitomycin	benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]]	21810436
D016685	Mitomycin	benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Mitomycin co-treated with Curcumin] results in decreased expression of RAD51 mRNA]	21810436
D016685	Mitomycin	Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]	21810436
D016685	Mitomycin	MAP2K1 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]]	21810436
D016685	Mitomycin	MAP2K2 protein inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]]	21810436
D016685	Mitomycin	[Mitomycin co-treated with Curcumin] results in decreased expression of RAD51 mRNA	21810436
D016685	Mitomycin	Mitomycin results in increased expression of RAD51 protein	21810436
D016685	Mitomycin	RAD51 results in decreased susceptibility to [Curcumin co-treated with Mitomycin]	21810436
D016685	Mitomycin	U 0126 promotes the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]]	21810436
D016685	Mitomycin	U 0126 promotes the reaction [[Mitomycin co-treated with Curcumin] results in decreased expression of RAD51 mRNA]	21810436
C406082	monomethylarsonous acid	monomethylarsonous acid results in decreased expression of RAD51 protein	24625837
C517284	monomethyl phthalate	monomethyl phthalate results in increased expression of RAD51 mRNA	26924002
D009151	Mustard Gas	BRCA2 protein inhibits the reaction [Mustard Gas affects the localization of RAD51 protein]	20435105
D009151	Mustard Gas	Mustard Gas affects the localization of RAD51 protein	20435105
D009151	Mustard Gas	RAD51 protein results in decreased susceptibility to Mustard Gas	20435105
C005246	myristicin	myristicin results in decreased expression of RAD51 mRNA	24792648
C554954	N-((3S)-1-azabicyclo(2.2.2)oct-3-yl)-1H-indazole-3-carboxamide hydrochloride	N-((3S)-1-azabicyclo(2.2.2)oct-3-yl)-1H-indazole-3-carboxamide hydrochloride results in increased expression of RAD51 mRNA	28174063
D037742	Nanotubes, Carbon	Nanotubes, Carbon analog results in increased expression of RAD51 mRNA	25554681
D037742	Nanotubes, Carbon	Nanotubes, Carbon results in increased expression of RAD51 mRNA	25554681
D009532	Nickel	Nickel results in increased expression of RAD51 mRNA	25583101
C022838	nickel chloride	nickel chloride results in decreased expression of RAD51 mRNA	28472268
C022838	nickel chloride	nickel chloride results in decreased expression of RAD51 protein	28472268
C022838	nickel chloride	nickel chloride affects the expression of RAD51 mRNA	22110744
D009534	Niclosamide	Niclosamide results in increased expression of RAD51 mRNA	31398420
C044387	N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine	N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of RAD51 mRNA	12888634
C010615	Nonidet P-40	Nonidet P-40 results in decreased expression of RAD51 mRNA	26552463
C434926	N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride	N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in decreased expression of RAD51 protein	25351371; 25995744;
C558013	NSC 689534	[NSC 689534 binds to Copper] which results in decreased expression of RAD51 mRNA	20971185
C025589	ochratoxin A	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [ochratoxin A results in decreased expression of RAD51]	24525463
C025589	ochratoxin A	ochratoxin A results in decreased expression of RAD51	24525463
C025589	ochratoxin A	SB 203580 inhibits the reaction [ochratoxin A results in decreased expression of RAD51]	24525463
C025589	ochratoxin A	TP53 mutant form inhibits the reaction [ochratoxin A results in decreased expression of RAD51]	24525463
C025589	ochratoxin A	ochratoxin A results in increased expression of RAD51 mRNA	24243707
C025589	ochratoxin A	ochratoxin A results in increased expression of RAD51 protein	24243707
D000077150	Oxaliplatin	[Oxaliplatin co-treated with Topotecan] results in decreased expression of RAD51 mRNA	25729387
D000077150	Oxaliplatin	Oxaliplatin results in decreased expression of RAD51 mRNA	25729387
D010100	Oxygen	Oxygen deficiency results in decreased expression of RAD51 mRNA	26516004
D010100	Oxygen	Oxygen deficiency results in decreased expression of RAD51 protein	25030372; 28472268;
D010126	Ozone	[NOTCH3 gene mutant form affects the susceptibility to Ozone] which results in increased expression of RAD51 mRNA	25658374
D010126	Ozone	TTPA protein affects the reaction [Ozone results in increased expression of RAD51 mRNA]	19555225
C410127	PCB 180	[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of RAD51 mRNA	25510870
C011272	perfosfamide	perfosfamide results in decreased expression of RAD51 mRNA	11754170
C058305	phenethyl isothiocyanate	phenethyl isothiocyanate results in decreased expression of RAD51 mRNA	26678675
D010634	Phenobarbital	[Diethylnitrosamine co-treated with Phenobarbital] results in increased expression of RAD51 mRNA	24535843
D010634	Phenobarbital	NR1I3 protein affects the reaction [Phenobarbital results in increased expression of RAD51 mRNA]	19482888
D010634	Phenobarbital	Phenobarbital results in increased expression of RAD51 mRNA	19482888; 23091169;
C030090	phosphoramide mustard	phosphoramide mustard affects the expression of RAD51 mRNA	25497287
C030090	phosphoramide mustard	phosphoramide mustard affects the expression of RAD51 protein	25497287
C030090	phosphoramide mustard	phosphoramide mustard results in decreased expression of RAD51 protein	26708502
C030090	phosphoramide mustard	phosphoramide mustard results in increased expression of RAD51 mRNA	26708502
D010795	Phthalic Acids	Phthalic Acids results in decreased expression of RAD51 mRNA	21061450
D048789	Phytoestrogens	Phytoestrogens results in increased expression of RAD51 mRNA	18310284
C121565	pifithrin	pifithrin inhibits the reaction [tetrachlorobenzoquinone results in decreased expression of RAD51 protein]	27989139
C006253	pirinixic acid	[pirinixic acid co-treated with PPARA] results in increased expression of RAD51 mRNA	20813756
C006253	pirinixic acid	pirinixic acid results in increased expression of RAD51 mRNA	17950772; 20813756; 23811191;
C006253	pirinixic acid	PPARA protein promotes the reaction [pirinixic acid results in increased expression of RAD51 mRNA]	17950772
D010936	Plant Extracts	Plant Extracts results in decreased expression of RAD51 mRNA	23557933
D010936	Plant Extracts	Plant Extracts results in increased expression of RAD51 mRNA	23557933
D028321	Plant Preparations	Plant Preparations affects the expression of RAD51 mRNA	16046712
D011078	Polychlorinated Biphenyls	Polychlorinated Biphenyls analog results in increased expression of RAD51 mRNA	16474171
C027373	potassium chromate(VI)	[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAD51 mRNA	22079256
C027373	potassium chromate(VI)	potassium chromate(VI) results in decreased expression of RAD51 mRNA	22079256; 22714537;
D011285	Pregnenolone Carbonitrile	[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Pregnenolone Carbonitrile] results in increased expression of RAD51 mRNA	23626729
D011285	Pregnenolone Carbonitrile	Pregnenolone Carbonitrile results in increased expression of RAD51 mRNA	22698814
D011353	Prodigiosin	Prodigiosin results in decreased expression of RAD51 mRNA	22579953
D011353	Prodigiosin	Prodigiosin results in decreased expression of RAD51 protein	22579953
D011353	Prodigiosin	pyrazolanthrone inhibits the reaction [Prodigiosin results in decreased expression of RAD51 mRNA]	22579953
D011353	Prodigiosin	RAD51 protein results in decreased susceptibility to Prodigiosin	22579953
D011353	Prodigiosin	SB 203580 inhibits the reaction [Prodigiosin results in decreased expression of RAD51 mRNA]	22579953
D011374	Progesterone	Progesterone affects the expression of RAD51 mRNA	17251523
C045950	propiconazole	propiconazole results in increased expression of RAD51 mRNA	21278054
D011441	Propylthiouracil	Propylthiouracil affects the expression of RAD51 mRNA	24780913
C432165	pyrazolanthrone	pyrazolanthrone inhibits the reaction [Prodigiosin results in decreased expression of RAD51 mRNA]	22579953
D011794	Quercetin	Quercetin inhibits the reaction [Doxorubicin results in decreased expression of RAD51 protein]	24902966
D011794	Quercetin	Quercetin results in increased expression of RAD51 protein	24902966
D000077185	Resveratrol	[Coumestrol co-treated with Resveratrol] results in increased expression of RAD51 mRNA	19167446
D000077185	Resveratrol	Resveratrol results in increased expression of RAD51 mRNA	15149879
C547185	riccardin D	riccardin D results in decreased expression of RAD51 mRNA	24069304
D012402	Rotenone	Rotenone results in increased expression of RAD51 mRNA	18191903
C093642	SB 203580	SB 203580 inhibits the reaction [ochratoxin A results in decreased expression of RAD51]	24525463
C093642	SB 203580	SB 203580 inhibits the reaction [Prodigiosin results in decreased expression of RAD51 mRNA]	22579953
D020123	Sirolimus	[Fulvestrant co-treated with Sirolimus] results in decreased expression of RAD51 mRNA	19016759
C017947	sodium arsenite	sodium arsenite results in increased expression of RAD51 mRNA	29301061
C017947	sodium arsenite	sodium arsenite results in decreased expression of RAD51 mRNA	16014739; 25787150;
C016104	sodium bichromate	sodium bichromate results in increased expression of RAD51 mRNA	22155349
C016104	sodium bichromate	sodium bichromate affects the expression of RAD51 mRNA	22110744
C016104	sodium bichromate	sodium bichromate results in increased expression of RAD51 mRNA	25993096
D018038	Sodium Selenite	Sodium Selenite results in decreased expression of RAD51 mRNA	10344722; 18175754;
D018038	Sodium Selenite	Sodium Selenite results in decreased expression of RAD51 protein	10344722
D053260	Soot	Soot results in increased expression of RAD51 mRNA	22461453; 26551751;
D000077210	Sunitinib	Sunitinib results in decreased expression of RAD51 mRNA	31533062
D013629	Tamoxifen	Tamoxifen results in decreased expression of RAD51 protein	17219426
D013739	Testosterone	[Testosterone co-treated with Calcitriol] results in decreased expression of RAD51 mRNA	21592394
D013739	Testosterone	Testosterone results in decreased expression of RAD51 mRNA	21592394
C000591600	tetrachlorobenzoquinone	pifithrin inhibits the reaction [tetrachlorobenzoquinone results in decreased expression of RAD51 protein]	27989139
C000591600	tetrachlorobenzoquinone	RAD51 protein inhibits the reaction [tetrachlorobenzoquinone results in increased expression of CASP3 protein modified form]	27989139
C000591600	tetrachlorobenzoquinone	RAD51 protein inhibits the reaction [tetrachlorobenzoquinone results in increased expression of H2AX protein modified form]	27989139
C000591600	tetrachlorobenzoquinone	RAD51 protein results in decreased susceptibility to tetrachlorobenzoquinone	27989139
C000591600	tetrachlorobenzoquinone	tetrachlorobenzoquinone affects the expression of RAD51 mRNA	27989139
C000591600	tetrachlorobenzoquinone	tetrachlorobenzoquinone affects the expression of RAD51 protein	27989139
C000591600	tetrachlorobenzoquinone	tetrachlorobenzoquinone affects the reaction [TP53 protein binds to RAD51 protein]	27989139
C000591600	tetrachlorobenzoquinone	tetrachlorobenzoquinone promotes the reaction [Dactinomycin results in decreased expression of RAD51 mRNA]	27989139
C000591600	tetrachlorobenzoquinone	TP53 protein promotes the reaction [tetrachlorobenzoquinone results in decreased expression of RAD51 protein]	27989139
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of RAD51 mRNA	16714409
D013749	Tetrachlorodibenzodioxin	[Endosulfan co-treated with Tetrachlorodibenzodioxin] results in increased expression of RAD51 mRNA	26159488
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of RAD51 mRNA	21570461
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of RAD51 mRNA	15667827
C005806	tetrachloroisophthalonitrile	tetrachloroisophthalonitrile results in increased expression of RAD51 protein	30586609
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of RAD51 mRNA	25613284
D013853	Thioacetamide	Thioacetamide results in increased expression of RAD51 mRNA	22659510
C009495	titanium dioxide	titanium dioxide results in increased expression of RAD51 mRNA	23557971
C009495	titanium dioxide	titanium dioxide results in increased expression of RAD51 mRNA	30012374
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of RAD51 mRNA	27404394; 27865774;
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution affects the expression of RAD51 mRNA	20133372
D019772	Topotecan	[Oxaliplatin co-treated with Topotecan] results in decreased expression of RAD51 mRNA	25729387
D014212	Tretinoin	Tretinoin results in decreased expression of RAD51 mRNA	18230668
D014241	Trichloroethylene	Trichloroethylene results in increased expression of RAD51 mRNA	25549359
C012589	trichostatin A	trichostatin A results in decreased expression of RAD51 mRNA	23770000
C015559	trimellitic anhydride	trimellitic anhydride results in increased expression of RAD51 mRNA	19042947
C016805	tris(1,3-dichloro-2-propyl)phosphate	tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of RAD51 mRNA	26179874
D000077288	Troglitazone	Troglitazone results in decreased expression of RAD51 mRNA	19140230
C113580	U 0126	U 0126 promotes the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]]	21810436
C113580	U 0126	U 0126 promotes the reaction [[Mitomycin co-treated with Curcumin] results in decreased expression of RAD51 mRNA]	21810436
D014520	Urethane	Urethane results in decreased expression of RAD51 mRNA	28818685
D014527	Uric Acid	NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of RAD51 mRNA]	23619996
D014527	Uric Acid	Uric Acid results in decreased expression of RAD51 mRNA	23619996
D014635	Valproic Acid	Valproic Acid results in decreased expression of RAD51 mRNA	20585447
D014635	Valproic Acid	Valproic Acid results in decreased expression of RAD51 mRNA	24913804
D014635	Valproic Acid	Valproic Acid results in increased expression of RAD51 mRNA	24913804
C029297	vinylidene chloride	vinylidene chloride results in increased expression of RAD51 mRNA	26682919
D024483	Vitamin K 3	Vitamin K 3 affects the expression of RAD51 mRNA	20044591
D000077337	Vorinostat	Vorinostat results in decreased expression of RAD51 protein	20646843
D014874	Water Pollutants, Chemical	Water Pollutants, Chemical results in increased expression of RAD51 mRNA	21315451
D015025	Zearalenone	Zearalenone results in decreased expression of RAD51 mRNA	27862621
D015025	Zearalenone	Zearalenone results in increased expression of RAD51 mRNA	28552778
D015025	Zearalenone	Zearalenone results in increased expression of RAD51 protein	28552778
C023616	zinc chromate	zinc chromate affects the phosphorylation of and affects the expression of RAD51 protein	25173789
C023616	zinc chromate	zinc chromate results in decreased expression of and results in decreased localization of RAD51 protein	27449664
D015034	Zinc Oxide	Zinc Oxide affects the splicing of and results in increased expression of RAD51 mRNA	30500950

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0002	3D-structure
KW-0007	Acetylation
KW-0025	Alternative splicing
KW-0067	ATP-binding
KW-0158	Chromosome
KW-0963	Cytoplasm
KW-0206	Cytoskeleton
KW-0225	Disease mutation
KW-0227	DNA damage
KW-0233	DNA recombination
KW-0234	DNA repair
KW-0238	DNA-binding
KW-0923	Fanconi anemia
KW-1017	Isopeptide bond
KW-0496	Mitochondrion
KW-0547	Nucleotide-binding
KW-0539	Nucleus
KW-0597	Phosphoprotein
KW-1185	Reference proteome
KW-0832	Ubl conjugation

Interpro

InterPro ID	InterPro Term
IPR003593	AAA+_ATPase
IPR011941	DNA_recomb/repair_Rad51
IPR013632	DNA_recomb/repair_Rad51_C
IPR016467	DNA_recomb/repair_RecA-like
IPR010995	DNA_repair_Rad51/TF_NusA_a-hlx
IPR027417	P-loop_NTPase
IPR033925	Rad51_DMC1_RadA
IPR020588	RecA_ATP-bd
IPR020587	RecA_monomer-monomer_interface

PROSITE

PROSITE ID	PROSITE Term
PS50162	RECA_2
PS50163	RECA_3

Pfam

Pfam ID	Pfam Term
PF08423	Rad51

Gene: RAD51

Basic information

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

Protein disorder information

Orthologous information

Identified variants/mutations related to cleft phenotype

Other genetic variants/mutations

Disease or phenotype associated information

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO:Biological Process

GO:Cellular Component

Reactome Pathway

Drugs and compounds information

Functional annotations

Keywords

Interpro

PROSITE

Pfam

Protein-protein interaction

Protein-miRNA interaction